Clinical trials: Diabetic Patients Type 1 and 2
Diabetes Mellitus, Type 2
BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (5 mg once daily) compared to placebo given for 24 weeks as add-on therapy to metformin in combination with a sulphonylurea in…
- Trial name
- NCT00602472
- Testing
- linagliptin
- Where
- 100 sites in Argentina, Belgium and 9 more
- Volunteers
- 1,058 people
- Sponsor
- Boehringer Ingelheim
Diabetic Kidney Disease, Diabetic Nephropathy
A Study in Participants With Diabetic Kidney Disease
The purpose of this study is to determine if LY2382770 is safe and effective at protecting kidney function in participants with kidney disease due to diabetes.
- Conditions
- Diabetic Kidney Disease, Diabetic Nephropathy, Diabetic Glomerulosclerosis
- Trial name
- NCT01113801
- Testing
- LY2382770
- Where
- 78 sites in United States, Australia and 5 more
- Volunteers
- 417 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)
The objective of this trial is to evaluate the pharmacodynamics, pharmacokinetics, safety, and tolerability of once daily oral administration of BI 10773 administered for 28 days in Japanese patients with T2DM.
- Trial name
- NCT00885118
- Testing
- BI 10773
- Where
- 5 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Boehringer Ingelheim
Diabetic Retinopathy
Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study
This study is to test whether or not 32 milligrams (mg) of ruboxistaurin a day over three years will reduce vision loss associated with diabetic retinopathy.
- Trial name
- NCT00604383
- Testing
- ruboxistaurin
- Where
- United States
- Volunteers
- 685 people
- Sponsor
- Chromaderm, Inc.
Diabetes Mellitus, Type 2
Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (5 mg once daily) compared to placebo given for 24 weeks as add-on therapy to metformin in patients with type 2 diabetes…
- Trial name
- NCT00601250
- Testing
- linagliptin
- Where
- 82 sites in United States, Czechia and 8 more
- Volunteers
- 701 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
A Study of PF-05175157 in Healthy Volunteers and Type 2 Diabetic Patients
The primary purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of PF-05175157 in healthy volunteers and patients with type 2 diabetes mellitus.
- Trial name
- NCT01396161
- Where
- 3 sites in United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hypoglycemia
Safety and Efficacy of a Novel Glucagon Formulation in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia
In this study, participants with Type 1 diabetes received insulin through an infusion into a vein to reduce their blood glucose, and then received nasal glucagon (NG) or glucagon for injection under the skin, and their blood…
- Trial name
- AMG102 (NCT01556594)
- Testing
- Nasal Glucagon 1 mg, Nasal Glucagon 2 mg, SC Glucagon
- Where
- Canada
- Volunteers
- 18 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes, Type 2 Diabetes
Smart Glucose Meter Project
Currently, in the U.S., 1 in 3 males and 2 in 5 females born after 2000 are expected to develop diabetes during his or her lifetime.
- Trial name
- NCT01341587
- Testing
- Telcare Blood Glucose Meter (BGM)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Maryland, Baltimore
Diabetic Nephropathy, Type 2 Diabetes Mellitus
ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial
The purpose of the study is to evaluate the effectiveness and safety of olmesartan versus placebo on the progression of diabetic renal disease.
- Conditions
- Diabetic Nephropathy, Type 2 Diabetes Mellitus, Proteinuria
- Trial name
- NCT00141453
- Testing
- olmesartan medoxomil
- Where
- 2 sites in China, Japan
- Volunteers
- 577 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
ACCU-CHEK® Aviva Expert Study: Does Use of a Bolus Advisor Improve Glycemic Control in Patients Not Achieving Optimal Control Using Multiple Daily Injections (MDI)?
This clinical, prospective, randomized, multi-center study determined if the use of an insulin bolus advisor improves glycemic control as measured by a change in HbA1c in patients failing multiple daily injection/intensified…
- Trial name
- ABACUS (NCT01460446)
- Testing
- Aviva Expert blood glucose meter, Aviva Nano blood glucose meter
- Where
- 33 sites in Germany, United Kingdom
- Volunteers
- 218 people
- Sponsor
- Hoffmann-La Roche
Diabetes, Type I, Diabetes, Type II
Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD
Coronary vascular dysfunction is highly prevalent among patients with known or suspected Coronary Artery Disease (CAD)1, increases the severity of inducible myocardial ischemia (beyond the effects of upstream coronary…
- Conditions
- Diabetes, Type I, Diabetes, Type II, Angina, Coronary Artery Disease
- Trial name
- RAND-CFR (NCT01754259)
- Testing
- Ranolazine
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Brigham and Women's Hospital
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Efficacy of Lubiprostone in Combination With Standard PEG Preparation
A large population-based study has shown diabetes to be an independent risk factor for colon cancer compared to the general population.
- Trial name
- NCT00689026
- Testing
- Lubiprostone, Polyethylene glycol with electrolytes
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Augusta University
Type 2 Diabetic Nephropathy
A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy
PF-03882845 is a compound proposed for treatment of type 2 diabetic nephropathy. The primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics of multiple doses of PF-03882845…
- Trial name
- NCT01488877
- Testing
- PF-03882845, Spironolactone
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Pfizer
Diabetic Retinopathy
A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy
The study's main purpose is to asses the safety, tolerability, and effect of oral administration of RG7774 on the severity of diabetic retinopathy (DR) in participants with moderately severe to severe non-proliferative diabetic…
- Trial name
- CANBERRA (NCT04265261)
- Testing
- RG7774
- Where
- 68 sites in United States, Australia and 5 more
- Volunteers
- 139 people
- Sponsor
- Hoffmann-La Roche
Type 2 Diabetes
Effect of Cycloset on Glycemic Control When Added to Glucagon-like Peptide 1 (GLP-1) Analogue Therapy
Purpose This study will examine the effect of the addition of Cycloset upon glucose metabolism (glycemic control including post prandial glucose metabolism) in individuals with inadequately controlled (HbA1c 7.5-10.0) type 2…
- Trial name
- NCT02299050
- Testing
- Cycloset
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Diabetes Mellitus, Type 2
BI 10773 add-on to Metformin in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and pharmacokinetics of five doses of BI 10773 compared to placebo given for 12 weeks as add-on therapy to on going metformin therapy in patients with T2DM…
- Trial name
- NCT00749190
- Testing
- BI 10773, sitagliptin
- Where
- 116 sites in United States, Argentina and 14 more
- Volunteers
- 495 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Closed Loop Glucose Control in Patients With Type 1 and Type 2 Diabetes
This is a proof of concept safety study of an artificial intelligence based closed loop glucose control system designed for use in the intensive care unit setting.
- Trial name
- NCT05644730
- Testing
- Fusion closed loop glucose control system
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Ideal Medical Technologies
Diabetic Macular Edema, Type 1 Diabetes Mellitus
Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease
The primary objective of the study is to determine if treatment with high-dose aflibercept (HD) at intervals of 12 or 16 weeks provides non-inferior best corrected visual acuity (BCVA) compared to aflibercept dosed every 8 weeks.
- Conditions
- Diabetic Macular Edema, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Trial name
- PHOTON (NCT04429503)
- Testing
- aflibercept, High-dose aflibercept
- Where
- 138 sites in United States, Canada and 6 more
- Volunteers
- 660 people
- Sponsor
- Regeneron Pharmaceuticals
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
A Study for Patients With Diabetes Mellitus (IOPA)
The purpose of this study is to compare glycemic control (HbA1c) in Chinese patients with type 1 or type 2 diabetes when treated with insulin lispro low mixture and human insulin 30/70.
- Trial name
- IOPA (NCT00420095)
- Testing
- Human insulin 30/70, Insulin lispro low mix
- Where
- 4 sites in China
- Volunteers
- 117 people
- Sponsor
- Eli Lilly and Company
Hypoglycemia, Diabetes Mellitus, Type 1
Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics
This is a blinded, randomized crossover study to compare the safety and efficacy of G-Pen (glucagon injection) to Lilly Glucagon (glucagon for injection [rDNA origin]) for hypoglycemia rescue of adult patients with type 1…
- Trial name
- NCT02656069
- Testing
- G-Pen (glucagon injection), Lilly Glucagon (glucagon injection [rDNA origin])
- Where
- 7 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- Xeris Pharmaceuticals